Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?

The Office of Hematology and Oncology Products originally targeted a four-month review goal for vismodegib, but review staff deemed such a compressed timeline not feasible.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America